• Summit Therapeutics posted a GAAP net loss of $189.4 million, or $(0.24) per share, for the first quarter ended March 31, 2026.
• GAAP operating expenses climbed to $195.2 million from $66.8 million, due to $61.7 million higher stock-based compensation tied to a 2025 modification of performance-based stock options.
• Cash, cash equivalents, and short-term investments fell to $598.7 million from $713.4 million.
• FDA accepted for filing a BLA for ivonescimab with a PDUFA goal action date of Nov. 14, 2026.
• Overall survival data from Akeso-sponsored Phase III HARMONi-6 will be presented at ASCO 2026 plenary on May 31, 2026, while Summit expects final PFS data for HARMONi-3 squamous in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604301632BIZWIRE_USPR_____20260430_BW114442) on April 30, 2026, and is solely responsible for the information contained therein.